Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AURA NASDAQ:ELVN NASDAQ:RARE NASDAQ:VERA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAURAAura Biosciences$6.31+0.5%$7.21$4.73▼$9.53$649.27M0.39466,410 shs531,094 shsELVNEnliven Therapeutics$44.86+5.4%$41.73$14.78▼$48.53$2.59B0.291.56 million shs1.51 million shsRAREUltragenyx Pharmaceutical$26.91+8.3%$24.17$18.29▼$42.37$2.45B0.371.54 million shs3.24 million shsVERAVera Therapeutics$35.01+4.0%$36.63$19.07▼$56.05$2.42B0.931.01 million shs1.12 million shsDon't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAURAAura Biosciences-2.64%-1.10%-18.86%-4.56%-1.88%ELVNEnliven Therapeutics+0.45%+17.83%+2.93%+56.15%+84.28%RAREUltragenyx Pharmaceutical-2.09%+9.04%-0.60%+21.46%-33.04%VERAVera Therapeutics-1.66%+5.85%-9.78%-12.13%+54.10%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAURAAura Biosciences$6.31+0.5%$7.21$4.73▼$9.53$649.27M0.39466,410 shs531,094 shsELVNEnliven Therapeutics$44.86+5.4%$41.73$14.78▼$48.53$2.59B0.291.56 million shs1.51 million shsRAREUltragenyx Pharmaceutical$26.91+8.3%$24.17$18.29▼$42.37$2.45B0.371.54 million shs3.24 million shsVERAVera Therapeutics$35.01+4.0%$36.63$19.07▼$56.05$2.42B0.931.01 million shs1.12 million shsDon't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAURAAura Biosciences-2.64%-1.10%-18.86%-4.56%-1.88%ELVNEnliven Therapeutics+0.45%+17.83%+2.93%+56.15%+84.28%RAREUltragenyx Pharmaceutical-2.09%+9.04%-0.60%+21.46%-33.04%VERAVera Therapeutics-1.66%+5.85%-9.78%-12.13%+54.10%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAURAAura Biosciences 2.25Hold$20.50224.88% UpsideELVNEnliven Therapeutics 2.83Moderate Buy$63.4041.33% UpsideRAREUltragenyx Pharmaceutical 2.82Moderate Buy$59.56121.34% UpsideVERAVera Therapeutics 2.75Moderate Buy$78.00122.79% UpsideCurrent Analyst Ratings BreakdownLatest AURA, ELVN, RARE, and VERA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/12/2026AURAAura Biosciences Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)6/9/2026ELVNEnliven Therapeutics Stifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$60.006/2/2026VERAVera Therapeutics Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$60.006/2/2026VERAVera Therapeutics William BlairSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform6/2/2026VERAVera Therapeutics The Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$90.006/2/2026VERAVera Therapeutics TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy6/2/2026ELVNEnliven Therapeutics MizuhoSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$45.00 ➝ $62.005/21/2026RAREUltragenyx Pharmaceutical Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$84.00 ➝ $96.005/15/2026VERAVera Therapeutics EvercoreSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$91.005/12/2026AURAAura Biosciences Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/12/2026AURAAura Biosciences Leerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$17.00(Data available from 6/17/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAURAAura BiosciencesN/AN/AN/AN/A$2.16 per shareN/AELVNEnliven TherapeuticsN/AN/AN/AN/A$7.74 per shareN/ARAREUltragenyx Pharmaceutical$673M3.94N/AN/A($0.83) per share-32.42VERAVera TherapeuticsN/AN/AN/AN/A$8.48 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAURAAura Biosciences-$106.19M-$1.74N/AN/AN/AN/A-78.12%-64.08%8/12/2026 (Estimated)ELVNEnliven Therapeutics-$103.69M-$1.67N/AN/AN/AN/A-21.04%-20.41%8/12/2026 (Estimated)RAREUltragenyx Pharmaceutical-$575M-$6.11N/AN/AN/A-91.03%-1,024.42%-45.78%8/4/2026 (Estimated)VERAVera Therapeutics-$299.61M-$5.54N/AN/AN/AN/A-74.86%-60.18%8/4/2026 (Estimated)Latest AURA, ELVN, RARE, and VERA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/21/2026Q1 2026AURAAura Biosciences-$0.40-$0.50-$0.10-$0.50N/AN/A5/11/2026Q1 2026AURAAura Biosciences-$0.40-$0.50-$0.10-$0.50N/AN/A5/7/2026Q1 2026ELVNEnliven Therapeutics-$0.44-$0.38+$0.06-$0.38N/AN/A5/7/2026Q1 2026VERAVera Therapeutics-$1.3284-$1.69-$0.3616-$1.69$0.43 millionN/A5/5/2026Q1 2026RAREUltragenyx Pharmaceutical-$1.4878-$1.84-$0.3522-$1.84$158.19 million$136.00 million3/30/2026Q4 2025AURAAura Biosciences-$0.43-$0.37+$0.06-$0.37N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAURAAura BiosciencesN/AN/AN/AN/AN/AELVNEnliven TherapeuticsN/AN/AN/AN/AN/ARAREUltragenyx PharmaceuticalN/AN/AN/AN/AN/AVERAVera TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAURAAura BiosciencesN/A7.097.09ELVNEnliven TherapeuticsN/A40.3240.32RAREUltragenyx PharmaceuticalN/A2.021.85VERAVera Therapeutics0.1513.6413.64Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAURAAura Biosciences96.75%ELVNEnliven Therapeutics95.08%RAREUltragenyx Pharmaceutical97.67%VERAVera Therapeutics99.21%Insider OwnershipCompanyInsider OwnershipAURAAura Biosciences6.30%ELVNEnliven Therapeutics3.00%RAREUltragenyx Pharmaceutical5.20%VERAVera Therapeutics15.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAURAAura Biosciences50103.39 million96.87 millionNot OptionableELVNEnliven Therapeutics5060.90 million59.08 millionOptionableRAREUltragenyx Pharmaceutical1,37198.49 million93.37 millionOptionableVERAVera Therapeutics4071.78 million60.37 millionOptionableAURA, ELVN, RARE, and VERA HeadlinesRecent News About These CompaniesVera Therapeutics (VERA) Appears Attractive After Latest FDA AgreementJune 17 at 3:34 PM | finance.yahoo.comRhenman & Partners Asset Management AB Has $21.27 Million Stock Position in Vera Therapeutics, Inc. $VERAJune 13, 2026 | marketbeat.comVera Therapeutics (VERA) Receives a Buy from Wells FargoJune 13, 2026 | theglobeandmail.comWill FDA Alignment on Atacicept’s eGFR Plan Reshape Vera Therapeutics’ (VERA) IgA Nephropathy NarrativeJune 8, 2026 | finance.yahoo.comA Look At Vera Therapeutics (VERA) Valuation After FDA Alignment On Accelerated IgA Nephropathy Trial AnalysisJune 8, 2026 | finance.yahoo.comAnalysts Offer Insights on Healthcare Companies: Vera Therapeutics (VERA) and Solid Biosciences (SLDB)June 7, 2026 | theglobeandmail.comAnalysts Are Bullish on Top Healthcare Stocks: Vera Therapeutics (VERA), OrthoPediatrics (KIDS)June 5, 2026 | theglobeandmail.comVera Therapeutics Grants Inducement Stock Awards to New EmployeesJune 5, 2026 | quiverquant.comQVera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)June 5, 2026 | markets.businessinsider.comVera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)June 5, 2026 | globenewswire.com$20 Billion: Inside Nvidia's VERA CPU Bet to Break the Intel-AMD DuopolyJune 4, 2026 | 247wallst.comVera Therapeutics moves closer to full approval for kidney disease drug after FDA alignmentJune 2, 2026 | msn.comVera Therapeutics Advances Atacicept Approval Path in IgA NephropathyJune 2, 2026 | tipranks.comVera Therapeutics Announces Alignment with U.S. FDA on Earlier ORIGIN Phase 3 Analysis to Support Potential Full Approval for Atacicept in Adults with IgA NephropathyJune 2, 2026 | globenewswire.comVera Therapeutics: Strong IgAN Data, But Differentiation Is Still PendingMay 27, 2026 | seekingalpha.comInvestment Firm Closes Out Entire $18.1 Million Position in Biotech Stock, According to Latest SEC FilingMay 26, 2026 | fool.comVera Therapeutics Stockholders Back Board, Governance ProposalsMay 26, 2026 | tipranks.comTimesSquare Capital Management LLC Makes New $12.79 Million Investment in Vera Therapeutics, Inc. $VERAMay 20, 2026 | marketbeat.comVera Therapeutics (NASDAQ:VERA) CEO Sells $679,690.00 in StockMay 14, 2026 | insidertrades.comThe Bull Case For Vera Therapeutics (VERA) Could Change Following Atacicept’s FDA Priority Review And Ramp-UpMay 11, 2026 | finance.yahoo.comVera Therapeutics (VERA) Gets a Buy from LifeSci CapitalMay 8, 2026 | theglobeandmail.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All Headlines3 Rare Earth Stocks That Win No Matter What China Does NextBy Bridget Bennett | May 24, 2026CAVA Group’s Stock Looks Delicious After Strong EarningsBy Chris Markoch | May 22, 2026USA Rare Earth Posts Strong Q1 2026 as Massive Serra Vera Deal LoomsBy Leo Miller | May 20, 2026Slice of the Pie: Why Yum’s Deal Lifts QSRBy Jeffrey Neal Johnson | June 3, 2026Mirum Pharma: A Rare Disease Growth Story to WatchBy Chris Markoch | May 20, 2026AURA, ELVN, RARE, and VERA Company DescriptionsAura Biosciences NASDAQ:AURA$6.31 +0.03 (+0.48%) Closing price 04:00 PM EasternExtended Trading$6.32 +0.01 (+0.16%) As of 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates. Its lead candidate is bel-sar, which is in late-stage clinical development for the treatment of patients with primary choroidal melanoma and other ocular oncology indications, as well as in early-stage clinical development in bladder cancer. The company also focuses on assessing the safety and efficacy of bel-sar in treating a range of other solid tumors, including bladder cancer as an alternative to bacillus calmetteguérin therapy. Aura Biosciences, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts.Enliven Therapeutics NASDAQ:ELVN$44.86 +2.31 (+5.43%) Closing price 04:00 PM EasternExtended Trading$44.25 -0.61 (-1.36%) As of 07:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations. The company is headquartered in Boulder, Colorado.Ultragenyx Pharmaceutical NASDAQ:RARE$26.91 +2.06 (+8.29%) Closing price 04:00 PM EasternExtended Trading$27.32 +0.41 (+1.52%) As of 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX111, an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc.; Solid Biosciences Inc.; Regeneron; Abeona; and Daiichi Sankyo Co., Ltd. The company was incorporated in 2010 and is headquartered in Novato, California.Vera Therapeutics NASDAQ:VERA$35.01 +1.34 (+3.98%) Closing price 04:00 PM EasternExtended Trading$35.83 +0.82 (+2.35%) As of 07:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial. It is also developing MAU868, a human monoclonal antibody for the treatment of BK viremia infections. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas CoreWeave Insider Sales Look Big, But Should Investors Worry? Critical Metals: Sizing Up This Tiny Rare-Earth Stock Making Big Moves Meta and Cloud Computing: Real Potential, or a Shot in the Dark? Gravity Check: Houston, SpaceX Has a Valuation Problem Okta’s AI Moment May Be Bigger Than Investors Realize Fox Captures The Living Room With $22B Roku Buy Dave & Buster’s Q1 Miss Raises the Stakes for Its Turnaround Plan Microsoft’s Xbox Problem Is Bigger Than a Console War Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
